418 related articles for article (PubMed ID: 32285126)
1. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
2. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
3. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract][Full Text] [Related]
4. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
5. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract][Full Text] [Related]
6. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
7. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Kipp D; H Wei A
Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
9. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Patel AA; Cahill K; Saygin C; Odenike O
Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Kim N; Norsworthy KJ; Subramaniam S; Chen H; Manning ML; Kitabi E; Earp J; Ehrlich LA; Okusanya OO; Vallejo J; Gehrke BJ; de Claro RA; Pazdur R
Clin Cancer Res; 2022 Aug; 28(16):3411-3416. PubMed ID: 35435961
[TBL] [Abstract][Full Text] [Related]
11. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
14. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
15. Decitabine and Cedazuridine.
Am J Health Syst Pharm; 2020 Oct; 77(22):1809-1811. PubMed ID: 32945859
[No Abstract] [Full Text] [Related]
16. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
17. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
19. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
20. Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Assouline S
Lancet Haematol; 2024 Mar; 11(3):e170-e171. PubMed ID: 38316134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
